MIAMI–(BUSINESS WIRE)–Ridgeback Biotherapeutics LP (“Ridgeback”), a biotechnology company experienced in antiviral drug development, announced today that the U.S. Food and Drug Administration (“FDA”) approved EbangaTM for the treatment of Ebola. Ebanga is now approved for treatment of infection caused by Zaire ebolavirus in adult and pediatric patients (including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection). Ebanga is the only FDA approved, single injection Ebola treatment which is available in a lyophilized form.

 

 

Credit: National Institute of Allergy and Infectious Diseases (NIAID)

Read more…